BCL2 and neuroblastoma: Previously, in 2015, a study by Olsen et al. [95] demonstrated that the use of navitoclax (a Bcl-2 family antagonist) was able to sensitize neuroblastoma and ES cell lines to chemotherapy agents, via apoptosis due to Bax activity, especially in N-myc amplified neuroblastoma.